Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Fusen Pharmaceutical Company Limited
福森藥業有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1652)

FURTHER EXTENSION OF COMPLETION DATE OF MAJOR TRANSACTION IN RELATION TO DEEMED DISPOSAL OF EQUITY INTEREST IN HENAN FUSEN PHARMACEUTICAL COMPANY LIMITED

Reference is made to the announcement and the circular (the "**Circular**") of Fusen Pharmaceutical Company Limited (the "**Company**") dated 18 June 2026 and 23 June 2026, respectively, in relation to, among other things, the Capital Increase, and the announcements of the Company dated 30 July 2026 and 8 October 2026 (the "**Further Extension Announcement**"), respectively, in relation to the extension of the Completion Date. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular and the Further Extension Announcement.

FURTHER EXTENSION OF COMPLETION DATE

As disclosed in the Further Extension Announcement, the Capital Increase Price Payment Date (i.e. the Completion Date) was scheduled to be extended to a date falling on or before 30 October 2026 pursuant to a second supplemental agreement to the Capital Increase Agreement dated 8 October 2026.

As additional time is required for the Investors to complete the internal arrangements necessary for payment of the Capital Increase Price for Completion, the Investors, Nanyang Hengsheng, Wealth Depot (HK) and the Target Company mutually agree to further extend the Capital Increase Price Payment Date to a date falling on or before 30 November 2026 pursuant to a third supplemental agreement to the Capital Increase Agreement dated 30 October 2026.

Save as disclosed above, all other terms and conditions of the Capital Increase Agreement remain unchanged and continue in full force and effect.

By order of the Board
Fusen Pharmaceutical Company Limited
Mr. Cao Zhiming
Chairman and Executive Director

Hong Kong, 30 October 2026

As at the date of this announcement, the Board of the Company comprises Mr. Cao Zhiming (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng and Ms. Meng Qingfen as executive Directors, and Mr. Lee Kwok Tung Louis, Dr. To Kit Wa and Mr. Yu Ho Ming as independent non-executive Directors.